This is a technical overview of an INVAMED device within the coronary artery disease & cardiac interventions portfolio. The specific combination of wires, balloons, atherectomy, and stents is determined by the interventional cardiologist based on lesion complexity, calcification, and overall clinical picture. As a medical device manufacturer, INVAMED develops technologies in this area; the information here is educational and not medical advice.
Background: Coronary Artery Disease and Percutaneous Coronary Intervention
The specific combination of wires, balloons, atherectomy, and stents is determined by the interventional cardiologist based on lesion complexity, calcification, and overall clinical picture. Coronary artery disease develops when atherosclerotic plaque accumulates within the arteries that supply the heart muscle, gradually narrowing the lumen and limiting blood flow. Percutaneous coronary intervention (PCI) is a catheter-based approach that reaches the coronary arteries through a small arterial access point, typically the radial or femoral artery.
Inwire PTCA Guidewire: Overview
PTCA guidewire line for coronary interventions, covering workhorse and complex-lesion (CTO) applications.
How It Works and Where It Fits
INVAMED groups its coronary portfolio around the sequence of a PCI case, offering access, lesion preparation, drug delivery, scaffolding, and closure devices. Rotational atherectomy modifies heavily calcified plaque so that balloons and stents can be delivered and expanded adequately. Guide extension catheters telescope through a guiding catheter to provide deep-vessel backup support during complex or tortuous PCI.
Key Considerations
- Thin-strut cobalt-chromium platforms are intended to balance deliverability with radial support in a range of vessel sizes.
- Lesion calcification is a central factor in planning, and heavily calcified plaque may call for rotational atherectomy before ballooning or stenting.
- All INVAMED coronary devices are intended for use by trained interventional cardiologists under fluoroscopic guidance and per the IFU.
Frequently Asked Questions
What is the reported restenosis performance of the ATLAS DES?
INVAMED reports clinical data showing target lesion revascularization rates below 5% at 12 months; this reflects studied performance and is not an individual guarantee.
Who decides between PCI and bypass surgery?
That decision is made by a clinical heart team based on coronary anatomy and individual factors; this article is educational and not medical advice.
What drug does the ATLAS stent release?
According to INVAMED, the ATLAS DES elutes sirolimus at 1 microgram per square millimeter with a sustained controlled-release profile.
About INVAMED
INVAMED operates a dedicated R&D center (INVAcenter) focused on minimally invasive device development. INVAMED is a medical device manufacturer headquartered in Ankara, Turkey, founded in 2005.
Clinical and Technical Context
INVAMED's ATLAS system elutes sirolimus at 1 microgram per square millimeter with a sustained controlled-release profile designed to cover the early healing window. According to INVAMED, clinical data for the ATLAS DES show target lesion revascularization rates below 5% at 12 months, a figure that reflects studied performance rather than an individual guarantee. Dual antiplatelet therapy duration is individualized to the clinical presentation and the patient's bleeding risk. Lesion calcification is a central factor in planning, and heavily calcified plaque may call for rotational atherectomy before ballooning or stenting. Coronary artery disease develops when atherosclerotic plaque accumulates within the arteries that supply the heart muscle, gradually narrowing the lumen and limiting blood flow. Selection among platforms is made by the operator according to vessel size, lesion characteristics, and deliverability requirements. INVAMED's AngioTEN Vascular Closure System is positioned for this access-site management role. Contemporary practice relies heavily on drug-eluting stents, which release an antiproliferative agent to limit the tissue overgrowth that can cause restenosis. Manufacturer figures such as the reported sub-5% target lesion revascularization rate describe studied performance, not guaranteed outcomes. Thin-strut cobalt-chromium platforms are intended to balance deliverability with radial support in a range of vessel sizes. INVAMED's Atlas line spans a cobalt-chromium drug-eluting version, a bare cobalt-chromium version described as offering high radial strength with minimal recoil, and a stainless-steel version. The specific combination of wires, balloons, atherectomy, and stents is determined by the interventional cardiologist based on lesion complexity, calcification, and overall clinical picture.
Related on INVAMED
- Coronary Artery Disease & Cardiac Interventions — product category
- Coronary and CTO Guidewires: Technology, Uses and Considerations
- Extender Drug Eluting PTCA Balloon Catheter (Paclitaxel): What Clinicians and Buyers Should Know
- Drug-eluting stent or Bare-metal stent? A Technical Comparison
Important Disclaimer
The information here is provided for educational purposes and to describe device technology; it is not a substitute for professional medical advice, diagnosis, or treatment. Only a licensed healthcare provider can determine whether a given procedure or device is appropriate for a specific patient. INVAMED products are restricted to use by qualified professionals following the official IFU. Regulatory clearance and labeling differ between regions, and not all products or indications are available in every market.
Reviewed by the INVAMED Medical Affairs team. Content is educational and technical in nature.